Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2004-11-12
2009-08-11
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S277100, C424S141100
Reexamination Certificate
active
07572443
ABSTRACT:
The invention provides novel compositions, methods, kits, and uses thereof relating to antimetastatic agents useful for treating neoplastic diseases.
REFERENCES:
patent: 4683202 (1987-07-01), Mullis
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5968511 (1999-10-01), Akita et al.
patent: 6133426 (2000-10-01), Gonzalez et al.
patent: 6627196 (2003-09-01), Baughman et al.
patent: 6639055 (2003-10-01), Carter et al.
patent: 0 404 097 (1990-12-01), None
patent: 902254 (1990-06-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 01/55178 (2001-08-01), None
patent: WO 02/085405 (2002-10-01), None
patent: WO 03/055516 (2003-07-01), None
Jain R. K. Scientific American, 271(1): 58-65, Jul. 1994.
Dillman R. O., Annals of Internal Medicine, 111:592-603, 1989.
Weiner L. M. Seminars in Oncology, 26 (4 Suppl 12): 41-50, Aug. 1999.
Zhou et al., Angiogenesis, vol. 3, p. 181-188, 1999.
Weidner et al., Am J Pathol, vol. 143, p. 401-9, 1993.
Yang et al., N Engl J Med. vol. 349, p. 427-434, 2003.
Gerber et al., PNAS, vol. 104, p. 3478-3483, 2007.
Passaniti et al., J Biol Chem. vol. 263 p. 7591-7603, 1998. Abstract.
Lundy et al.,., J. Surg. Oncol. vol. 31 p. 260-7. 1986. Abstract.
Wong et al.,., Amer. J. of Path. vol. 161, p. 749-53. 2002.
Baker, et al., “Suppression of human colorectal carcinoma cell growth by wild-type p53.”Science249:912-915 (1990).
Barbas, et al., “Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem.”Proc. Nat'l Acad. Sci. USA89:4457-4461 (1992).
Boemer, et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes.”J. Immunol.147:86-95 (1991).
Breitling, et al., “A surface expression vector for antibody screening.”Gene104:147-153 (1991).
Burton, et al., “A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.”Proc. Nat'l Acad. Sci USA88:10134-10137 (1991).
Cao, et al., “Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration.”Am. J. Physiol. Cell Physiol.282:C1181-C1190 (2002).
Caton and Koprowski, “Influenza virus hemagglutinin-specific antibodies isolated from a combinatorial expression library are closely related to the immune response of the donor.”Proc. Nat'l Acad. Sci. USA87:6450-6454 (1990).
Chang, et al., “Expression of antibody Fab domains on bacteriophage surfaces. Potential use for antibody selection.”J. Immunol.147:3610-3614 (1991).
Chothia and Lesk, “Canonical structures for the hypervariable regions of immunoglobulins.”J. Mol. Biol.196:901-917 (1987).
Clackson, et al., “Making antibody fragments using phage display libraries.”Nature352:624-628 (1991).
Cole, et al., “The EBV-hybridoma technique and its application to human lung cancer” inMonoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77-96 (1985).
Desprez, et al., “A novel pathway for mammary epithelial cell invasion by helix-loop-helix protein Id-1.”Mol. Cell Biol.18:4577-4588 (1998).
Duncan, et al., “Genetic evidence for functional redundancy of platelet/endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions.”J. Immunol.162:3022-3030 (1999).
Eckert and Kunkel, “DNA polymerase fidelity and the polymerase chain reaction”.PCR Methods and Applications1:17-24 (1991).
Ellisen and Haber, “Hereditary breast cancer.”Annu Rev Med.49:425-36 (1998).
Evan and Littlewood, “A matter of life and cell death.”Science28:1317-22 (1998).
Fishwild, et al., “High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.”Nature Biotechnol.14:845-51 (1996).
Foulds, “The natural history of cancer.”J Chronic Dis.8:2-37 (1958).
Hawkins and Winter, “Cell selection strategies for making antibodies from variable gene libraries: trapping the memory pool.”Eur. J. Immunol.22:867-870 (1992).
Holliger, et al., “Diabodies: small bivalent and bispecific antibody fragments.”Proc. Nat'l Acad. Sci. USA90:6444-6448 (1993).
Hoogenboom and Winter, “By-passing immunisation. Human antibodies from synthetic repertoires of germline VHgene segments rearranged in vitro.”J. Mol. Biol.227:381-388 (1992).
Hoogenboom, et al., “Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains.”Nucleic Acids Res.19:4133-4137 (1991).
Huse, et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda.”Science246:1275-1281 (1989).
Jones, et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse.”Nature321:522-525 (1986).
Kabat, et al.,Sequences of Proteins of Immunological Interest, NIH Publ No. 91-3242, vol. I, pp. 647-669 (1991).
Kang, et al., “Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces.”Proc. Nat'l Acad. Sci. USA88: 4363-4366 (1991).
Kerr, et al., “Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.”Br. J. Cancer26:239-257 (1972).
Kohler and Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity.”Nature256:495-497 (1975).
Lee, et al., “Human retinoblastoma susceptibility gene: cloning, identification, and sequence.”Science235:1394-1399 (1987).
Lerner, et al., “Antibodies without immunization.”Science258:1313-1314 (1992).
Lonberg, et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications.”Nature368:856-859 (1994).
Lonberg and Huszar, “Human antibodies from transgenic mice.”Intem. Rev. Immunol.13:65-93 (1995).
Lowman, et al., “Selecting high-affinity binding proteins by monovalent phage display .”Biochemistry30:10832-10838 (1991).
Marks, et al., “By-passing immunization: building high affinity human antobodies by chain shuffling.”Biotechnol.10:779-783 (1992).
Marks, et al., “Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system.”J. Biol. Chem.267:16007-16010 (1992).
Marks, et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage.”J. Mol. Biol.222:581-597 (1991).
Mattila, et al., “Fidelity of DNA synthesis by theThermococcus litoralisDNA polymerase—an extremely heat stable enzyme with proofreading activity.”Nucl. Acids Res.19:4967-4973 (1991).
Molecular Probes Product Information, “Labeled Donkey Anti-Goat IgG Antibodies.” MP11055, Sep. 20, 1-2 (2001).
Morrison, “Success in specification.”Nature368:812-813 (1994).
Morrison, et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains.”Proc. Nat'l Acad. Sci. USA81:6851-6955 (1984).
Mullinax, et al., “Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage γ immunoexpression library.”Proc. Nat'l Acad. Sci. USA87:8095-8099 (1990).
Nakada, et al., “Antibodies against the first Ig-like domain of human platelet endothelial cell adhesion molecule-1 (PECAM-1) that Inhibit PECAM-1-dependent homophilic adhesion block in vivo neutrophil recruitment.”J. Immunol.164:452-462 (2000).
Needleman and Wunsch, “A general method applicable to the se
California Pacific Medical Center
Flick Karen E.
Helms Larry R.
Yao Lei
LandOfFree
Anti-PECAM therapy for metastasis suppression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-PECAM therapy for metastasis suppression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-PECAM therapy for metastasis suppression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4063261